• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
YANG Qian, CHEN Nannan, YOU Qidong, XU Xiaoli. Research progress on stimulator of interferon genes (STING) agonists[J]. Journal of China Pharmaceutical University, 2022, 53(3): 253-263. DOI: 10.11665/j.issn.1000-5048.20220301
Citation: YANG Qian, CHEN Nannan, YOU Qidong, XU Xiaoli. Research progress on stimulator of interferon genes (STING) agonists[J]. Journal of China Pharmaceutical University, 2022, 53(3): 253-263. DOI: 10.11665/j.issn.1000-5048.20220301
shu

Research progress on stimulator of interferon genes (STING) agonists

  • 1.

    Patent Examination Corporation Beijing Center of the Patent Office, China National Intellectual Property Administration, Beijing 100160

  • 2.

    Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing 211198, China

Funds: This study was supported by the National Natural Science Foundation of China (No.82073692, No.82073766)
More Information
  • Received Date: October 11, 2021
  • Revised Date: May 22, 2022
    Graphical Abstract
    • Abstract
  • Stimulator of interferon genes (STING) is an important factor in the auto-immune response of our bodies.Considering the mechanism of activating CD8+ T cells after the activation of STING protein, the combination of STING agonists and immune checkpoint inhibitors for the treatment of tumor immunotherapy has good clinical application prospect.In this paper, the research progress of molecular types, mechanism of action and structural modifications of STING agonists were reviewed.The developing tendency were outlined to provide some references for further investigation.
    • FullText(HTML)
    • References (57)
  • [1]
    . Nature，2008，455（7213）：674-678.
    [2]
    Liu SQ，Cai X，Wu JX，et al. Phosphorylation of innate immune adaptor proteins MAVS，STING，and TRIF induces IRF3 activation［J］. Science，2015，347（6227）：aaa2630.
    [3]
    Zhang CG，Shang GJ，Gui X，et al. Structural basis of STING binding with and phosphorylation by TBK1［J］. Nature，2019，567（7748）：394-398.
    [4]
    Li XD，Wu JX，Gao DX，et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects［J］. Science，2013，341（6152）：1390-1394.
    [5]
    Ouyang SY，Song XQ，Wang YY，et al. Structural analysis of the STING adaptor protein reveals a hydrophobic dimer interface and mode of cyclic di-GMP binding［J］. Immunity，2012，36（6）：1073-1086.
    [6]
    Shu C，Yi GH，Watts T，et al. Structure of STING bound to cyclic di-GMP reveals the mechanism of cyclic dinucleotide recognition by the immune system［J］. Nat Struct Mol Biol，2012，19（7）：722-724.
    [7]
    Tu SM，Liu YP，Chen Y. Research progress of cGAS-STING in tumor metastasis［J］. Acta Pharm Sin（药学学报），2020，55（3）：398-406.
    [8]
    Zhang H，You QD，Xu XL. Targeting Stimulator of interferon genes （STING）：a medicinal chemistry perspective［J］. J Med Chem，2020，63（8）：3785-3816.
    [9]
    Ji LY，Hao J，Wang GC，et al. Research progress on stimulator of interferon genes agonists for cancer immunotherapy［J］. J China Pharm Univ（中国药科大学学报），2020，51（1）：1-9.
    [10]
    Sun Y，Yang BW，Liu TC，et al. Advances in research of STING agonists［J］. Chin. J. Med. Chem（中国药物化学杂志），2020，30（5）：296-309.
    [11]
    Kalia D，Merey G，Nakayama S，et al. Nucleotide，c-di-GMP，c-di-AMP，cGMP，cAMP，（p）ppGpp signaling in bacteria and implications in pathogenesis［J］. Chem Soc Rev，2013，42（1）：305-341.
    [12]
    Li LY，Yin Q，Kuss P，et al. Hydrolysis of 2′3′-cGAMP by ENPP1 and design of nonhydrolyzable analogs［J］. Nat Chem Biol，2014，10（12），1043-1048.
    [13]
    Shaw BR，Sergueev D，He K，et al. Boranophosphate backbone：a mimic of phosphodiesters，phosphorothioates，and methyl phosphonates［J］. Methods Enzymol，2000，313：226-257.
    [14]
    Glick G，Ghosh S，Roush WR，et al. Cyclic dinucleotide analogs for treating conditions associated with STING （stimulator of interferon genes） activity：
    WO2018045204A1［P］. 2018-03-08.
    [15]
    Katibah GE，Kanne D，Sung L，et al. Compositions and methods for activating “stimulator of interferon gene”-dependent signaling：
    WO2017075477A1［P］. 2017-05-04.
    [16]
    Altman MD，Andresen B，Chang W，et al. Cyclic di-nucleotide compounds as STING agonists：
    WO2017027646A1［P］. 2017-02-16.
    [17]
    Wu RG，Yi DW. Cyclic dinucleotide compound，preparation method and application thereof：
    CN109694397A［P］. 2019-04-30.
    [18]
    Kanne DB，Ndubaku CO，BrumL JR，et al. Locked nucleic acid cyclic dinucleotide compounds and uses thereof：
    WO2018009466A1［P］. 2018-01-11.
    [19]
    Lioux T，Mauny MA，Lamoureux A，et al. Design，synthesis，and biological evaluation of novel cyclic adenosine-inosine monophosphate （cAIMP） analogs that activate Stimulator of interferon genes （STING）［J］. J Med Chem，2016，59（22）：10253-10267.
    [20]
    Fink BE，Zhao Y，Chen L，et al. Cyclic dinucleotides as anticancer agents：
    WO2019079261A1［P］. 2019-04-25.
    [21]
    Vyskocil S，Ciavarri J，Cullis C，et al. STING modulator compounds，and methods of making and using：
    WO2019092660A1［P］. 2019-05-16.
    [22]
    Kim DS，Endo A，Fang FG，et al. E-7766，a macrocycle-bridged stimulator of interferon genes （STING） agonist with potent pan-genotypic activity［J］. ChemMedChem，2021，16（11）：1740-1743.
    [23]
    Li YM，Wu JJ，Zhang BD，et al. Novel STING agonist，and preparation method and application thereof：
    CN111592570A［P］. 2020-08-28.
    [24]
    Peng JB，Guo SC，Liu Y，et al. Tumor immunity compound and application thereof：
    CN111349132A［P］，2020-06-30.
    [25]
    Guo SC，Liu Y，Peng JB. Compound for tumor immunity and application thereof：
    CN111655712A［P］. 2020-09-11.
    [26]
    Prantner D，Perkins DJ，Lai W，et al. 5，6-Dimethylxanthenone-4-acetic acid （DMXAA） activates Stimulator of interferon gene （STING）-dependent innate immune pathways and is regulated by mitochondrial membrane potential［J］. J Biol Chem，2012，287（47）：39776-39788.
    [27]
    Gao P，Ascano M，Zillinger T，et al. Structure-function analysis of STING activation by c［G（2′，5′）pA（3′，5′）p］and targeting by antiviral DMXAA［J］. Cell，2013，154（4）：748-762.
    [28]
    Cavlar T，DeimLing T，Ablasser A，et al. Species-specific detection of the antiviral small-molecule compound CMA by STING［J］. EMBO J，2013，32（10）：1440-1450.
    [29]
    Gao P，Zillinger T，Wang WY，et al. Binding-pocket and lid-region substitutions render human STING sensitive to the species-specific drug DMXAA［J］. Cell Rep，2014，8（6）：1668-1676.
    [30]
    Chamberlain BT，Rice JM，Finith FE，et al. Oxoacridinyl acetic acid derivatives and methods of use：
    WO2019100061A1［P］. 2019-05-23.
    [31]
    Hou S，Lan XJ，Li W，et al. Design，synthesis and biological evaluation of acridone analogues as novel STING receptor agonists［J］. Bioorg Chem，2020，95：103556.
    [32]
    Zhang YB，Sun Z，Pei JW，et al. Identification of α-mangostin as an agonist of human STING［J］. ChemMedChem，2018，13（19）：2057-2064.
    [33]
    Ramanjulu JM，Pesiridis GS，Yang JS，et al. Design of amidobenzimidazole STING receptor agonists with systemic activity［J］. Nature，2018，564（7736）：439-443.
    [34]
    Deng YQ，Sun J. Heterocyclic compound capable of enhancing immune activity，preparation method therefor and application in medicine：
    WO2021000770A1［P］. 2021-01-07.
    [35]
    Xi QM，Wang MJ，Jia WQ，et al. Design，synthesis，and biological evaluation of amidobenzimidazole derivatives as Stimulator of interferon genes （STING） receptor agonists［J］. J Med Chem，2020，63（1）：260-282.
    [36]
    Wang XJ，Xi QM，Jin J，et al. Aromatic ring or aromatic heterocyclic imidazole compound，preparation method and pharmaceutical application thereof：
    CN112279835A［P］. 2021-01-29.
    [37]
    Li GY，Tian Q，Niu XD，et al. Heterocyclic amide compound，pharmaceutical composition containing heterocyclic amide compound，preparation method of heterocyclic amide compound and application of heterocyclic amide compound：
    CN110963997A［P］. 2020-04-07.
    [38]
    Li J，Zhang DY，Pan F，et al. Macro-cyclic immuno-modulator：
    CN111471056A［P］. 2020-07-31.
    [39]
    Li J，Zhang DY，Pan F，et al.
    Immunomodulator：
    CN111499617A［P］. 2020-08-07.
    [40]
    Leit De Moradei SM，Romero DL，Knight J，et al. STING Heterocycle agonists and uses thereof：
    WO2020132549A1［P］. 2020-06-25.
    [41]
    Leit De Moradei SM，Romero DL. STING pyrazole agonists and uses thereof：
    WO2020132566A1［P］. 2020-06-25.
    [42]
    Leit De Moradei SM，Romero DL，Knight J，et al. STING agonists and uses thereof：
    WO2020132582A1［P］. 2020-06-25.
    [43]
    Slassi A，Dove P，Rosa DA，et al. Heteroaromatic-fused imidazolyl amides，compositions and uses thereof as STING agonists：
    WO2020010451A1［P］. 2020-01-16.
    [44]
    Wu L，Lajkiewicz N，Yao W. Heteroaryl amide compounds as STING activators：
    WO2020146237A1［P］. 2020-07-16.
    [45]
    Zhang A，Geng MY，Song ZL，et al. Benzimidazole dimer and preparation method and application thereof：
    CN113087668［P］. 2021-07-09.
    [46]
    Cemerski S，Cumming JN，Kopinja JE，et al.
    Benzo［b］thiophene STING agonists for cancer treatment：
    WO2019027858A1［P］. 2019-02-07.
    [47]
    Zhang A，Geng MY，Ding CY，et al. Benzothiophene compound as well as pharmaceutical composition and application thereof：
    CN111393404A［P］. 2020-07-10.
    [48]
    Pan BS，Perera SA，Piesvaux JA，et al. An orally available non-nucleotide STING agonist with antitumor activity［J］. Science，2020，369（6506）：eaba6098.
    [49]
    Altman MD，Cash BD，Childers ML. Benzothiophenes and related compounds as sting agonists：
    WO2019195124A1［P］. 2019-10-10.
    [50]
    Fensome A，Fisher EL，Gajiwala KS. Polyheterocyclic modulators of STING （stimulator of interferon genes）：
    WO2021059136A1［P］. 2021-04-01.
    [51]
    Jiang S，He CY，Zhang KY. Pyrimido five-membered heterocyclic compounds or pharmaceutically acceptable salts and isomers thereof，preparation method of pyrimido five-membered heterocyclic compounds or pharmaceutically acceptable salts and isomers thereof，pharmaceutical compositions and application of pyrimido five-membered heterocyclic compounds or pharmaceutically acceptable salts and isomers thereof and pharmaceutical compositions：
    CN113024563A［P］. 2021-06-25.
    [52]
    Shi J，Liu CL，Zhang B，et al. Genome mining and biosynthesis of kitacinnamycins as a STING activator［J］. Chem Sci，2019，10（18）：4839-4846.
    [53]
    Chin EN，Yu CG，Vartabedian VF，et al. Antitumor activity of a systemic STING-activating non-nucleotide cGAMP mimetic［J］. Science，2020，369（6506）：993-999.
    [54]
    Hanada R，Kokubo M，Kurono M，et al. STING -agonist compound：
    WO2020075790A1［P］. 2020-04-16.
    [55]
    Banerjee M，Middya S，Basu S，et al. Heterocyclic small molecule modulators of human STING：
    WO2018234807A1［P］. 2018-12-27.
    [56]
    Banerjee M，Middya S，Basu S，et al. Small molecule modulators of human STING：
    WO2018234808A1［P］. 2018-12-27.
    [57]
    Lu DF，Shang GJ，Li J，et al. Activation of STING by targeting a pocket in the transmembrane domain［J］. Nature，2022，604（7906）：557-562.
    • Related Articles

  • Related Articles

    [1]LI Yue, XU Kai, YANG Rui, YANG Huiying. Application of ultra-high performance convergence chromatography-tandem quadrupole time-of-flight mass spectrometry in the analysis of Span composition[J]. Journal of China Pharmaceutical University, 2024, 55(6): 742-749. DOI: 10.11665/j.issn.1000-5048.2024010502
    [2]LI Yan, JIA Huanhuan, HUANG Qing, YUAN Yaozuo, CHEN Minhui, ZHANG Jinlin. Impurity spectra of lansoprazole enteric-coated preparations by high performance liquid chromatography-high resolution orbital trap mass spectrometry[J]. Journal of China Pharmaceutical University, 2023, 54(5): 577-585. DOI: 10.11665/j.issn.1000-5048.2023042601
    [3]HU Zhaoliang, ZOU Wenyu, SONG Min, HANG Taijun, LU Yuting. Correlation between in-vivo mercury exposure from Cinnabaris and memory disorders in juvenile rat[J]. Journal of China Pharmaceutical University, 2023, 54(4): 483-489. DOI: 10.11665/j.issn.1000-5048.2023042603
    [4]YU Lili, CHU Tingting, HOU Chenzhi, WANG Youmei, DI Bin. Quantitative determination of 10 illicit drugs in wastewater by liquid-liquid extraction-ultra performance liquid chromatography-tandem mass spectrometry[J]. Journal of China Pharmaceutical University, 2021, 52(6): 707-712. DOI: 10.11665/j.issn.1000-5048.20210608
    [5]XIE Feng, LI Zhan-bin, TAN Hong, WANG Yan-jiao. Determination of chromium in capsule shells by ultrasonic wave promoting dissolution-graphite furnace atomic absorption spectrometry[J]. Journal of China Pharmaceutical University, 2012, 43(3): 281-282.
    [6]SHEN Wei-yang, ZHONG Shao-peng, CHEN Jian-qiu. Interaction between silicotungstic acid,silicon tungsten-cobalt heteropoly acid and bovine serum albumin by fluorescence spectrometry[J]. Journal of China Pharmaceutical University, 2011, 42(2): 131-135.
    [7]Determination of Arsenic in Chinese Herbal Extract by Flow Injection-Hydride Generation-Atomic Absorption Spectrometry[J]. Journal of China Pharmaceutical University, 2003, (4): 48-50.
    [8]Determination of Trace Arsenic in Spirulina plaensis Tablets by Flow Injection Hydride Generation Atomic Fluorescence Spectrometry[J]. Journal of China Pharmaceutical University, 1998, (6): 473-474.
    [9]Determination of Arsenic in Chinese Traditional Patent Drug XINLINGWAN by Zeeman Graphite Furnace Atomic Absorption Spectrometry[J]. Journal of China Pharmaceutical University, 1995, (2): 94-96.
    [10]Determination of 11 Metal Elements in Chinese Traditional Medicine by Use of Atomic Absorption Spectrophotometry[J]. Journal of China Pharmaceutical University, 1991, (1): 33-35.

Catalog

    Get Citation
    PDF
    XML
    Article views (489) PDF downloads (590) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：292773

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return